These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 33109399)

  • 1. Identification of methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate (CYH33) as an orally bioavailable, highly potent, PI3K alpha inhibitor for the treatment of advanced solid tumors.
    Xiang HY; Wang X; Chen YH; Zhang X; Tan C; Wang Y; Su Y; Gao ZW; Chen XY; Xiong B; Gao ZB; Chen Y; Ding J; Meng LH; Yang CH
    Eur J Med Chem; 2021 Jan; 209():112913. PubMed ID: 33109399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (
    Rageot D; Bohnacker T; Keles E; McPhail JA; Hoffmann RM; Melone A; Borsari C; Sriramaratnam R; Sele AM; Beaufils F; Hebeisen P; Fabbro D; Hillmann P; Burke JE; Wymann MP
    J Med Chem; 2019 Jul; 62(13):6241-6261. PubMed ID: 31244112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of 2-(2-aminopyrimidin-5-yl)-4-morpholino-N-(pyridin-3-yl)quinazolin-7-amines as novel PI3K/mTOR inhibitors and anticancer agents.
    Peng W; Tu ZC; Long ZJ; Liu Q; Lu G
    Eur J Med Chem; 2016 Jan; 108():644-654. PubMed ID: 26731167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel PARP/PI3K dual inhibitors with high efficiency against BRCA-proficient triple negative breast cancer.
    Wang J; He G; Li H; Ge Y; Wang S; Xu Y; Zhu Q
    Eur J Med Chem; 2021 Mar; 213():113054. PubMed ID: 33309164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of N-(2-chloro-5-(3-(pyridin-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide (FD274) as a highly potent PI3K/mTOR dual inhibitor for the treatment of acute myeloid leukemia.
    Yang C; Chen Y; Wu T; Gao Y; Liu X; Yang Y; Ling Y; Jia Y; Deng M; Wang J; Zhou Y
    Eur J Med Chem; 2023 Oct; 258():115543. PubMed ID: 37329712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI3Kα inhibitor CYH33 triggers antitumor immunity in murine breast cancer by activating CD8
    Sun P; Zhang X; Wang RJ; Ma QY; Xu L; Wang Y; Liao HP; Wang HL; Hu LD; Kong X; Ding J; Meng LH
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34373258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and pharmacological evaluation of 2-arylurea-1,3,5-triazine derivative (XIN-9): A novel potent dual PI3K/mTOR inhibitor for cancer therapy.
    Sun X; Zhang B; Luo L; Yang Y; He B; Zhang Q; Wang L; Xu S; Zheng P; Zhu W
    Bioorg Chem; 2022 Dec; 129():106157. PubMed ID: 36209563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitor.
    Ruel R; Thibeault C; L'Heureux A; Martel A; Cai ZW; Wei D; Qian L; Barrish JC; Mathur A; D'Arienzo C; Hunt JT; Kamath A; Marathe P; Zhang Y; Derbin G; Wautlet B; Mortillo S; Jeyaseelan R; Henley B; Tejwani R; Bhide RS; Trainor GL; Fargnoli J; Lombardo LJ
    Bioorg Med Chem Lett; 2008 May; 18(9):2985-9. PubMed ID: 18395443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel potent PI3K/mTOR dual-target inhibitors based on scaffold hopping: Design, synthesis, and antiproliferative activity.
    Yang Y; Sun X; Luo L; Peng R; Yang R; Cheng Z; Lv Y; Li H; Tang Q; Zhu W; Qiao D; Xu S
    Arch Pharm (Weinheim); 2023 Dec; 356(12):e2300403. PubMed ID: 37840368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.
    Beaufils F; Cmiljanovic N; Cmiljanovic V; Bohnacker T; Melone A; Marone R; Jackson E; Zhang X; Sele A; Borsari C; Mestan J; Hebeisen P; Hillmann P; Giese B; Zvelebil M; Fabbro D; Williams RL; Rageot D; Wymann MP
    J Med Chem; 2017 Sep; 60(17):7524-7538. PubMed ID: 28829592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of novel 1,3,5-triazine derivatives as potent inhibitor of cervical cancer via dual inhibition of PI3K/mTOR.
    Hu J; Zhang Y; Tang N; Lu Y; Guo P; Huang Z
    Bioorg Med Chem; 2021 Feb; 32():115997. PubMed ID: 33440319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and biological evaluation of novel 6-(pyridin-3-yl) quinazolin-4(3H)-one derivatives as potential anticancer agents via PI3K inhibition.
    Yang H; Li Q; Su M; Luo F; Liu Y; Wang D; Fan Y
    Bioorg Med Chem; 2021 Sep; 46():116346. PubMed ID: 34403956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alkylsulfonamide-containing quinazoline derivatives as potent and orally bioavailable PI3Ks inhibitors.
    Hei YY; Zhang SQ; Feng Y; Wang J; Duan W; Zhang H; Mao S; Sun H; Xin M
    Bioorg Med Chem; 2019 Oct; 27(20):114930. PubMed ID: 31176568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and bioevaluation of diaryl urea derivatives as potential antitumor agents for the treatment of human colorectal cancer.
    Wu CF; Wang QC; Chen R; Zhou HL; Wu TT; Du Y; Zhang NN; Zhang HM; Fan ZY; Wang LL; Hu CJ; Sang ZP; Li HL; Wang L; Tang L; Zhang JQ
    Eur J Med Chem; 2022 Feb; 229():114055. PubMed ID: 34971874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and SAR of novel 4-morpholinopyrrolopyrimidine derivatives as potent phosphatidylinositol 3-kinase inhibitors.
    Chen Z; Venkatesan AM; Dehnhardt CM; Ayral-Kaloustian S; Brooijmans N; Mallon R; Feldberg L; Hollander I; Lucas J; Yu K; Kong F; Mansour TS
    J Med Chem; 2010 Apr; 53(8):3169-82. PubMed ID: 20334367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and structure-activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffold.
    Wurz RP; Liu L; Yang K; Nishimura N; Bo Y; Pettus LH; Caenepeel S; Freeman DJ; McCarter JD; Mullady EL; Miguel TS; Wang L; Zhang N; Andrews KL; Whittington DA; Jiang J; Subramanian R; Hughes PE; Norman MH
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5714-20. PubMed ID: 22832322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and antitumor activity of novel thiophene- triazine derivatives bearing arylurea unit as potent PI3K/mTOR inhibitorss.
    Xu S; Luo L; Sun X; Yang Y; Guo Q; Jiang Z; Wu Y
    Bioorg Med Chem; 2023 Jan; 78():117133. PubMed ID: 36599263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of 2-Methyl-2-(4-(2-methyl-8-(1
    Yang J; Liu Y; Lan S; Yu S; Ma X; Luo D; Shan H; Zhong X; Yan G; Li R
    J Med Chem; 2022 Oct; 65(19):12781-12801. PubMed ID: 36191148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3Kα-selective inhibitor CYH33 in breast cancer.
    Liu XL; Xu YC; Wang YX; Chen Y; Wang BB; Wang Y; Chen YH; Tan C; Hu LD; Ma QY; Zhang YC; Sun YM; Gao YL; Yang CH; Ding J; Meng LH
    Cancer Lett; 2018 Oct; 433():273-282. PubMed ID: 30003928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repressing MYC by targeting BET synergizes with selective inhibition of PI3Kα against B cell lymphoma.
    Chen ZQ; Cao ZR; Wang Y; Zhang X; Xu L; Wang YX; Chen Y; Yang CH; Ding J; Meng LH
    Cancer Lett; 2022 Jan; 524():206-218. PubMed ID: 34688842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.